ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2835

Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus

Mariana Postal1, Karina O. Peliçari1, Nailu A. Sinicato2, Aline Tamires Lapa1, Fernando A. Peres1, André Moreno Morcillo3, Lilian TL Costallat3 and Simone Appenzeller4, 1Medicine, State University of Campinas, Campinas, Brazil, 2Pediatrics, State University of Campinas, Campinas, Brazil, 3State University of Campinas, Campinas, Brazil, 4Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Autoimmunity, Biomarkers, cytokines and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  While autoantibodies production and immune complex deposition are cornered as hallmark features of systemic lupus erythematosus (SLE), there is growing evidence to propose the pathogenic role of cytokines in this disease. The aim of this follow-up study was to evaluate the sera levels of Th1 cytokines and Th2 in SLE patients, associating these cytokines with disease activity, clinical and laboratory manifestations and also, to assess Th1 and Th2 cytokines levels could be potential biomarkers.

Methods:  Consecutive SLE patients followed at the Rheumatology unit of the State University of Campinas were enrolled in this follow-up study. Healthy volunteers, matched by age and sex, were included as control group. A complete clinical, laboratory and neurological evaluation was performed in all subjects. Neurological manifestations were analyzed according to the ACR classification criteria. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and long-term therapy. Clinical, laboratory evaluation and blood withdrawal was performed every 4 months for 1 year. Sera for stored. Sera cytokines levels were performed by enzyme linked immunosorbent assay (ELISA) at the end of the study. Data were compared by non-parametric tests.

Results:  Two hundred and eighteen (210 women) SLE patients, with a mean age of 42.62 ±11.98 years were included. The control group, matched by age and sex, consisted of 46 (40 women) healthy volunteers with a mean age of 40.04±13.54 years. Only IL-6 remained significantly increased in SLE patients [median sera levels (pg/mL): T0 2.13; T1 1.96; T2 2.52; T3 2.37] compared to healthy controls [T0 0.91 (p<0.001); T1 0.91 (p<0.001); T2 0.93 (p<0.001); T3 1.3 (p=0.042)] over time. Sera IL-10 levels correlated with disease activity in all evaluations (T0 r=0.28 p<0.001; T1 r=0.23 p=0.001; T2 r=0.19 p=0.007 T3 r=0.14 p=0.049). We also observed an association between sera IL-10 levels and nephritis in all evaluations (T0 p=0.008; T1 p=0.036; T2 p=0.024 and T3 p=0.005). In the paired analyses, significant variation in IFN-γ [median sera levels (pg/mL): T0 25.7; T1 31.22; T2 35.98; T3 26.3; p=0.026), IL-12 (T0 1.86; T1 0.94; T2 1.09; T3 1.34; p<0.001), IL-4 (T0 0.41; T1 0.34; T2 0.34; T3 0.5; p=0.001) and IL-10 (T0 0.98; T1 0.94; T2 1.09; T3 1.34; p<0.001) was observed. There was no significant variation in TNF-α (T0 2.84; T1 2.67; T2 2.83; T3 2.71; p=0.304) and IL-6 (T0 2.13; T1 1.96; T2 2.52; T3 2.37; p=0.241). In the paired analyses, we also observed an association between INF-γ (p=0.039) and IL-10 (p<0.001) and neuropsychiatric manifestations in SLE patients.

Conclusion: IL-10 may be considered a biomarker for disease activity and nephritis in SLE. IFN-γ and IL-10 may identify patients with CNS involvement. Identifying new SLE biomarkers might be a useful tool to sub-classify patients and predict which clinical manifestation these patients might develop.


Disclosure: M. Postal, None; K. O. Peliçari, None; N. A. Sinicato, None; A. T. Lapa, None; F. A. Peres, None; A. M. Morcillo, None; L. T. Costallat, None; S. Appenzeller, None.

To cite this abstract in AMA style:

Postal M, Peliçari KO, Sinicato NA, Lapa AT, Peres FA, Morcillo AM, Costallat LT, Appenzeller S. Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/longitudinal-analysis-of-th1-and-th2-cytokines-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-analysis-of-th1-and-th2-cytokines-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology